Updates on HER2-Directed ADCs Across Solid Tumors : Episode 3

Opinion

Video

July 12, 2024

ADCs Targeting HER2+ Gynecologic Cancers

Author(s):

Vijayakrishna Gadi, MD, University of Illinois College of Medicine,Susana Campos, MD, MPH

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.

EP: 1.Assessing HER2 Status Across Tumor Types

EP: 2.ADCs Targeting HER2+ Breast Cancer

Now Viewing

EP: 3.ADCs Targeting HER2+ Gynecologic Cancers

EP: 4.Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP: 5.ADCs Targeting GI Cancers

EP: 6.ADCs Targeting HER2+ Lung Cancer

EP: 7.Impact of ADCs on Brain Metastases

EP: 8.ADCs Targeting HER2+ GU Cancers

EP: 9.Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP: 10.The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP: 11.Managing ILD and Pneumonitis Risk From ADCs

EP: 12.Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP: 13.Managing Hematologic AEs Associated with ADC Treatments

EP: 14.Management of Emetogenicity of Antibody-Drug Conjugates

EP: 15.ADC Sequencing

EP: 16.Emerging ADCs in Development

EP: 17.Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP: 18.The Future for HER2-Directed ADCs

EP: 19.Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

What is the potential for T-DXd in other gynecologic cancers?

Latest Conference Coverage

RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors

TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512